Last updated on November 2017

Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (TRIPLE)


Brief description of study

Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (TRIPLE)

Detailed Study Description

Pegloticase IV Open Label 16 weeks study treatment period with opt-in dosing extension of an additional 8 weeks.

Clinical Study Identifier: TX3970

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Theresa Bass-Goldman, CCRC

The Center for Rheumatology and Bone Research
Wheaton, MD USA
  Connect »